Abstract
BackgroundImmunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have